12,372 trials
Hyponatremia
Primary: Participants With Adverse Events (AEs) — 105; 76; 73; 19 participants
Gastric Ulcer
Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy(EC) Aspirin 325 mg — 10; 23 participants — p=0.020
Crohn Disease
Primary: Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study C87088 (up to 272 Weeks) — 89.6 percentage of subjects
Asthma
Primary: FEV1 Percent Predicted — 51.7; 52.6 percent predicted of FEV1
Pulmonary Disease, Chronic Obstructive
Primary: FEV1 AUC0-3h Response — -0.006; 0.188; 0.279; 0.293 L — p=<0.0001
Influenza
Primary: Geometric Mean Titers of Influenza Antibodies Before and Following Vaccination With a Quadrivalent Influenza Vaccine — 257; 589; 382; 782 Titers (1/dilution)
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentages of Subjects With Serum Bactericidal Activity Using Human Serum (hSBA) Titers ≥ 4 or hSBA Titers ≥ 5 (Strain M10713) Following a 2-dose Primary Series of…
Renal Failure
Primary: Evaluation of T(Max) for Envarsus XR, Astagraf XL and Prograf. — 5.91; 1.93; 1.48 hour
Gaucher Disease
Primary: Hemoglobin — 10.6; 11.2; 13.5; 11.9 g/dL
Alcohol Dependence · Stress Disorders, Post-Traumatic
Primary: Number of Drinking Days — 11.04; 9.21 days
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Morning Forced Expiratory Volume in 1 Second (FEV1) at Day 85 — 0.116; 0.091 Liters (L)
Hypertriglyceridemia
Primary: Percent Change in Triglyceride for All Subjects — -28.1; -10.2 Percentage of change (%) — p=0.017
Spinal Cord Injuries · Spinal Cord Diseases
Primary: Number of Participants Achieving a Reduction in Pain Intensity of 30% or More — 18; 26; 35 participants — p=<.05
Alcohol Dependence · Schizophrenia
Primary: Number of Drinking Days — 10.7; 7.6 days
Relapsing-Remitting Multiple Sclerosis
Primary: Adjusted Mean Estimates for Injection-Related Adverse Event Rate Per Year in the Core Period — 70.403; 35.275 events per year — p=0.0006